Moreover, pharmaceutical inhibition of FFAR2 signaling significantly facilitated the immune checkpoint blockade (ICB) mediated tumor suppression, suggesting the great potential of FFAR2 as a novel target for cancer immune therapy. Here, FFAR2 is linked to cancer.